Yabao Pharmaceutical Group Co Ltd (600351) - Total Liabilities
Based on the latest financial reports, Yabao Pharmaceutical Group Co Ltd (600351) has total liabilities worth CN¥585.77 Million CNY (≈ $85.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Yabao Pharmaceutical Group Co Ltd (600351) investment intensity to see how much of total assets are deployed in long-term investments.
Yabao Pharmaceutical Group Co Ltd - Total Liabilities Trend (1999–2024)
This chart illustrates how Yabao Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 600351 asset base.
Yabao Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yabao Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Henglin Chair Industry Co Ltd Class A
SHG:603661
|
China | CN¥6.72 Billion |
|
Ronglian Group Ltd
SHE:002642
|
China | CN¥1.39 Billion |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
China | CN¥2.51 Billion |
|
Tanla Platforms Limited
NSE:TANLA
|
India | Rs10.94 Billion |
|
Lsb Industries Inc
NYSE:LXU
|
USA | $685.38 Million |
|
Bank of Kaohsiung Ltd
TW:2836
|
Taiwan | NT$329.13 Billion |
|
UEM Sunrise Bhd
KLSE:5148
|
Malaysia | RM5.64 Billion |
|
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
STU:2TZ
|
Germany | €2.91 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Yabao Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600351 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yabao Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yabao Pharmaceutical Group Co Ltd (1999–2024)
The table below shows the annual total liabilities of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥649.02 Million ≈ $94.97 Million |
-24.56% |
| 2023-12-31 | CN¥860.33 Million ≈ $125.89 Million |
-23.49% |
| 2022-12-31 | CN¥1.12 Billion ≈ $164.54 Million |
+1.02% |
| 2021-12-31 | CN¥1.11 Billion ≈ $162.88 Million |
-6.93% |
| 2020-12-31 | CN¥1.20 Billion ≈ $175.00 Million |
-24.70% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.41 Million |
-12.42% |
| 2018-12-31 | CN¥1.81 Billion ≈ $265.37 Million |
+24.71% |
| 2017-12-31 | CN¥1.45 Billion ≈ $212.79 Million |
-1.42% |
| 2016-12-31 | CN¥1.48 Billion ≈ $215.86 Million |
-6.27% |
| 2015-12-31 | CN¥1.57 Billion ≈ $230.30 Million |
+15.29% |
| 2014-12-31 | CN¥1.37 Billion ≈ $199.76 Million |
-9.36% |
| 2013-12-31 | CN¥1.51 Billion ≈ $220.39 Million |
+18.69% |
| 2012-12-31 | CN¥1.27 Billion ≈ $185.69 Million |
+14.16% |
| 2011-12-31 | CN¥1.11 Billion ≈ $162.66 Million |
-22.19% |
| 2010-12-31 | CN¥1.43 Billion ≈ $209.06 Million |
+8.99% |
| 2009-12-31 | CN¥1.31 Billion ≈ $191.82 Million |
+55.33% |
| 2008-12-31 | CN¥843.93 Million ≈ $123.49 Million |
+21.56% |
| 2007-12-31 | CN¥694.23 Million ≈ $101.59 Million |
+2.74% |
| 2006-12-31 | CN¥675.74 Million ≈ $98.88 Million |
-13.41% |
| 2005-12-31 | CN¥780.42 Million ≈ $114.20 Million |
+30.15% |
| 2004-12-31 | CN¥599.65 Million ≈ $87.75 Million |
+72.97% |
| 2003-12-31 | CN¥346.67 Million ≈ $50.73 Million |
+104.44% |
| 2002-12-31 | CN¥169.57 Million ≈ $24.81 Million |
-0.01% |
| 2001-12-31 | CN¥169.58 Million ≈ $24.82 Million |
+25.23% |
| 2000-12-31 | CN¥135.42 Million ≈ $19.82 Million |
+16.95% |
| 1999-12-31 | CN¥115.80 Million ≈ $16.94 Million |
-- |
About Yabao Pharmaceutical Group Co Ltd
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 a… Read more